Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on February 13, 2012

Published on Wednesday, 01 February 2012 09:17 Written by TradersHuddle Staff

BOTHELL, Wash.-( Business Wire )-

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2011 financial results on Monday, February 13, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Monday, February 13, 2012

1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)

• Telephone 877-941-8609 (domestic) or 480-629-9692 (international); conference ID 4509854
• Webcast available at http://www.seattlegenetics.com in the Investors and News section

REPLAY access

• Telephone replay will be available beginning at approximately 3:30 p.m. PT on Monday, February 13, 2012, through 5:00 p.m. PT on Wednesday, February 15, 2012, by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4509854
• Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The FDA granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.Peggy Pinkston, This e-mail address is being protected from spambots. You need JavaScript enabled to view it.